Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2019

View Archived Issues

FDA clears IND for NantKwest's CD19.t-haNK cell therapy

GlaxoSmithKline initiates phase I study of HBV therapeutic vaccines

Pfizer initiates phase II study of PF-06700841 topical cream for atopic dermatitis

First-in-human data presented for TAS-119

TVB-2640 in combination with bevacizumab results in promising PFS in patients with recurrent GBM

Phase I data for CC-90010 in patients with advanced solid tumors and non-Hodgkin's lymphoma

Clinical study foreseen for Immunic's autoimmune disease candidate IMU-935

Microbiome metabolism influences drug responses

Novel ruthenium(II) complex induces apoptosis and inhibits angiogenesis in tumor animal models

Rifamycin SV-MMX evaluated in phase II study for acute uncomplicated diverticulitis

Promising results of phase I trial of CAL-02 in severe community-acquired pneumococcal pneumonia

TXNRD1 blockade found to play protective role in acute lung injury

New gene variants found to protect against osteoporosis in patients with Gaucher's disease

Phase III ELEVATE-TN trial of Calquence in previously untreated CLL meets primary endpoint

Asclepius initiates phase I/II study of BCMA CAR-NK cells in relapsed/refractory multiple myeloma

Partial response observed in ongoing phase II study of BN-Brachyury for chordoma

Phase III study of Ninlaro in systemic AL amyloidosis misses first of two primary endpoints

Vaccitech initiates phase IIb study of MVA-NP+M1 universal flu vaccine in Belgium

Concert Pharmaceuticals presents phase I preliminary data for CTP-692

Novartis discovers HBsAg secretion inhibitors

New mGlu2 negative allosteric modulators synthesized at Sumitomo Dainippon Pharma

Senju Pharmaceutical synthesizes new PAC1 and/or VPAC1 and/or VPAC2 receptor ligands

Hepagene Therapeutics patents MEK kinase 5 inhibitors

Metabomed identifies acetyl-coenzyme A synthetase, cytoplasmic inhibitors

InflaRx reports topline results from phase IIb SHINE study of IFX-1 in hidradenitis suppurativa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...